Article Details

Go or no go? FDA firsts for Imfinzi, Enhertu and roflumilast - Evaluate Pharma

Retrieved on: 2022-07-01 14:20:52

Tags for this article:

Click the tags to see associated articles and topics

Go or no go? FDA firsts for Imfinzi, Enhertu and roflumilast - Evaluate Pharma. View article details on hiswai:

Excerpt

As the summer months roll on, Astrazeneca's Imfinzi could become the first immunotherapy approved in front-line biliary tract cancer, ...

Article found on: www.evaluate.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up